Managing Multidrug Resistance in Cancer (el. knyga) (skaityta knyga) | knygos.lt

Aprašymas

Plant-derived compounds and nanotechnology converge to combat drug-resistant cancers

Over 90% of cancer deaths in metastatic cases are linked to drug resistance, yet few references integrate phytochemical therapeutics with nanotechnology-based delivery. Managing Multidrug Resistance in Cancer: Emerging Mechanisms and Plant-based Strategies assembles expert contributors who critically evaluate preclinical and clinical evidence on plant-derived molecules that inhibit efflux pumps, restore apoptosis, and reverse resistance in breast, lung, colorectal, ovarian, and hematologic malignancies.

Contributors detail nanotechnology-based biodegradable delivery systems that enhance selectivity, bioavailability, and retention time while reducing toxicity. The volume covers AI and machine-learning tools for diagnostic improvement, personalized medicine frameworks, and clinical trial data on phytochemical efficacy. Global MDR cancer scenarios in both developed and developing nations receive dedicated analysis, addressing accessibility and economic feasibility of plant-derived treatments.

Key topics also include:

• Mechanisms of intrinsic and acquired resistance to tamoxifen, EGFR-TKIs, and platinum-based chemotherapeutics across common cancer types
• Structural diversity and multi-target action of phytochemicals that distinguish them from single-target synthetic agents in MDR reversal
• Nanocarrier design principles for enhancing solubility, tumor targeting, and controlled release of plant-derived anticancer compounds
• Translational pathways from preclinical phytochemical research to clinical application, including current trial methodologies and outcomes
• Toxicity reduction strategies that integrate natural compounds into advanced therapeutic platforms for improved patient survival rates

Designed for researchers and clinicians at the intersection of oncology, pharmacology, and nanotechnology, this volume serves cancer scientists, pharmacognosy specialists, and biomedical professionals seeking low-toxicity treatment approaches. Pharmaceutical developers exploring translational applications of phytochemicals and nanocarriers in precision oncology will find targeted, evidence-based guidance throughout.